Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference
Codiak BioSciences (Nasdaq: CDAK) announced participation in the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 8:00 am ET. CEO Douglas E. Williams, Ph.D., will engage in a fireside chat, which will be available via a live webcast on the company's website. An archived replay will be accessible for 90 days post-event. Codiak is focused on developing exosome-based therapeutics, utilizing its engEx® Platform to target various disease areas, including oncology and infectious diseases.
- None.
- None.
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak’s Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Company will also be hosting one-on-one meetings at the conference.
A live webcast of the fireside chat will be available on the Investors & Media section of the Codiak website at www.codiakbio.com. An archived replay will be available for approximately 90 days following the fireside chat.
About Codiak BioSciences
Codiak is a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx® Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx® Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, infectious disease and rare disease.
For more information, please visit www.codiakbio.com.
Investor Contact:
Christopher Taylor
VP, Investor Relations and Corporate Communications
T: 617-949-4220
E: investor@codiakbio.com
Media Contact:
Cory Tromblee
Scient PR
media@codiakbio.com
FAQ
What is the event Codiak BioSciences will participate in on November 30, 2022?
Who will represent Codiak BioSciences at the HealthCONx Conference?
What time is the Codiak BioSciences fireside chat during the conference?
Where can I watch the Codiak BioSciences fireside chat?
How long will the Codiak BioSciences fireside chat be available for replay?
What is Codiak BioSciences known for?
